neurodegenerative disease neurodegenerative disease
Stories About

neurodegenerative disease

In college, Amylyx cofounders Josh Cohen and Justin Klee dreamed of finding a treatment for diseases like ALS. When their drug's promise did not pan out, they pulled it voluntarily from the market. Amylyx Pharmaceuticals hide caption

toggle caption
Amylyx Pharmaceuticals

Lots of drug companies talk about putting patients first — but this one actually did

  • <iframe src="https://www.npr.org/player/embed/1251409920/1251419014" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">

In patients with Alzheimer's disease, a substance called beta-amyloid can form toxic clumps in between neurons. Drugs like lecanemab are designed to remove amyloid-beta from the brain. National Institute on Aging, National Institutes of Health. hide caption

toggle caption
National Institute on Aging, National Institutes of Health.

An Alzheimer's drug is on the way, but getting it may still be tough. Here's why

  • Download
  • <iframe src="https://www.npr.org/player/embed/1184071997/1184268073" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript